The Impact of Clinical Symptoms and Endoscopic and Histologic Disease Activity on Health-related Quality of Life in Patients with Ulcerative Colitis Following Treatment with Multimatrix Mesalazine

Overview

Journal Qual Life Res

Specialties Pharmacology
Rehabilitation Medicine

Date 2021 Mar 2

PMID 33651279

Authors

Aaron Yarlas

Mary Kaye Willian

Arpita Nag

Affiliations

Soon will be listed here.

Abstract

Purpose: Studies of patients with ulcerative colitis (UC) report that reduced clinical symptoms and endoscopic activity predict better health-related quality of life (HRQoL). However, no study has examined the joint and unique associations of clinical and endoscopic activity with HRQoL, nor of histologic inflammation and HRQoL. These post hoc analyses evaluated whether reduced clinical, endoscopic, and histologic disease activity were uniquely associated with improved HRQoL for adults with active mild-to-moderate UC receiving once-daily 4.8 g/day multimatrix mesalazine for 8 weeks.

Methods: Assessments at baseline and week 8 (i.e., treatment completion) included clinical and endoscopic activity (modified UC-Disease Activity Index), histology (Geboes scoring), and HRQoL (Short Inflammatory Bowel Disease Questionnaire [SIBDQ]; SF-12v2 Health Survey [SF-12v2]). Associations among each type of disease activity and HRQoL were examined by correlations and by mean changes in SIBDQ and SF-12v2 scores between disease activity subgroups (e.g., achievement of clinical remission; mucosal healing). Regression models estimated unique variance in HRQoL accounted by each type of disease activity.

Results: Within the analysis sample (n = 717), patients with reduced clinical and endoscopic activity had significantly larger improvements in all HRQoL domains (p < 0.001), as did patients in both endoscopic and clinical remission compared to patients in endoscopic remission only (p < 0.05). Patients with histologic activity post-treatment scored significantly worse on all HRQoL domains than patients with no activity (p < 0.05). Correlations and regression models found that decreases in clinical and endoscopic activity were associated with improvements in HRQoL domain scores.

Conclusions: Clinical symptoms and mucosal health have separable, distinct impacts on UC patients' HRQoL.

Citing Articles

Optimizing 5-aminosalicylate for moderate ulcerative colitis: expert recommendations from the Asia-Pacific, Middle East, and Africa Inflammatory Bowel Disease Coalition.

Akyuz F, An Y, Begun J, Aniwan S, Bui H, Chan W Intest Res. 2024; 23(1):37-55.

PMID: 39492666 PMC: 11834365. DOI: 10.5217/ir.2024.00089.

References

Shah S, Colombel J, Sands B, Narula N . Mucosal Healing Is Associated With Improved Long-term Outcomes of Patients With Ulcerative Colitis: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2016; 14(9):1245-1255.e8. DOI: 10.1016/j.cgh.2016.01.015. View

Guyatt G, Mitchell A, Irvine E, Singer J, Williams N, Goodacre R . A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology. 1989; 96(3):804-10. View

Feagan B, Reinisch W, Rutgeerts P, Sandborn W, Yan S, Eisenberg D . The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am J Gastroenterol. 2007; 102(4):794-802. DOI: 10.1111/j.1572-0241.2007.01094.x. View

Colombel J, Rutgeerts P, Reinisch W, Esser D, Wang Y, Lang Y . Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011; 141(4):1194-201. DOI: 10.1053/j.gastro.2011.06.054. View

Hefti M, Chessin D, Harpaz N, Steinhagen R, Ullman T . Severity of inflammation as a predictor of colectomy in patients with chronic ulcerative colitis. Dis Colon Rectum. 2009; 52(2):193-7. PMC: 2753491. DOI: 10.1007/DCR.0b013e31819ad456. View

Han S, Gregory W, Nylander D, Tanner A, Trewby P, Barton R . The SIBDQ: further validation in ulcerative colitis patients. Am J Gastroenterol. 2000; 95(1):145-51. DOI: 10.1111/j.1572-0241.2000.01676.x. View

Regueiro M, Rodemann J, Kip K, Saul M, Swoger J, Baidoo L . Physician assessment of ulcerative colitis activity correlates poorly with endoscopic disease activity. Inflamm Bowel Dis. 2010; 17(4):1008-14. DOI: 10.1002/ibd.21445. View

Rutter M, Saunders B, Wilkinson K, Rumbles S, Schofield G, Kamm M . Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004; 126(2):451-9. DOI: 10.1053/j.gastro.2003.11.010. View

Sandborn W, Van Assche G, Reinisch W, Colombel J, DHaens G, Wolf D . Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2011; 142(2):257-65.e1-3. DOI: 10.1053/j.gastro.2011.10.032. View

10.

Jharap B, Sandborn W, Reinisch W, DHaens G, Robinson A, Wang W . Randomised clinical study: discrepancies between patient-reported outcomes and endoscopic appearance in moderate to severe ulcerative colitis. Aliment Pharmacol Ther. 2015; 42(9):1082-92. PMC: 5049645. DOI: 10.1111/apt.13387. View

11.

Travis S, Higgins P, Orchard T, van der Woude C, Panaccione R, Bitton A . Review article: defining remission in ulcerative colitis. Aliment Pharmacol Ther. 2011; 34(2):113-24. DOI: 10.1111/j.1365-2036.2011.04701.x. View

12.

Sandborn W, Feagan B, Marano C, Zhang H, Strauss R, Johanns J . Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2013; 146(1):85-95. DOI: 10.1053/j.gastro.2013.05.048. View

13.

Irvine E, Feagan B, Rochon J, Archambault A, Fedorak R, Groll A . Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology. 1994; 106(2):287-96. DOI: 10.1016/0016-5085(94)90585-1. View

14.

Bland J, Altman D . Correlation in restricted ranges of data. BMJ. 2011; 342:d556. DOI: 10.1136/bmj.d556. View

15.

Peyrin-Biroulet L, Ferrante M, Magro F, Campbell S, Franchimont D, Fidder H . Results from the 2nd Scientific Workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease. J Crohns Colitis. 2011; 5(5):477-83. DOI: 10.1016/j.crohns.2011.06.009. View

16.

Gibson P, Vaizey C, Black C, Nicholls R, Weston A, Bampton P . Relationship between disease severity and quality of life and assessment of health care utilization and cost for ulcerative colitis in Australia: a cross-sectional, observational study. J Crohns Colitis. 2013; 8(7):598-606. DOI: 10.1016/j.crohns.2013.11.017. View

17.

Reinisch W, Van Assche G, Befrits R, Connell W, DHaens G, Ghosh S . Recommendations for the treatment of ulcerative colitis with infliximab: a gastroenterology expert group consensus. J Crohns Colitis. 2012; 6(2):248-58. DOI: 10.1016/j.crohns.2011.11.001. View

18.

Solomon D, Yarlas A, Hodgkins P, Karlstadt R, Yen L, Kane S . The impact of MMX mesalazine on disease-specific health-related quality of life in ulcerative colitis patients. Aliment Pharmacol Ther. 2012; 35(12):1386-96. DOI: 10.1111/j.1365-2036.2012.05107.x. View

19.

Bitton A, Peppercorn M, Antonioli D, Niles J, Shah S, Bousvaros A . Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology. 2001; 120(1):13-20. DOI: 10.1053/gast.2001.20912. View

20.

Peyrin-Biroulet L, Sandborn W, Sands B, Reinisch W, Bemelman W, Bryant R . Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. Am J Gastroenterol. 2015; 110(9):1324-38. DOI: 10.1038/ajg.2015.233. View